China Gives Greenlight to Allergan's XEN® Registration for the Surgical Management of Refractory Glaucoma
-- XEN® Becomes the First Medical Product Approved by Using Real World Evidence inChina -- DUBLIN, April 2, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced China's National Medical Products Administration (NMPA) approved the registration of Allergan's XEN® Gel Stent on March 26, 202...
Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
DUBLIN, July 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced a voluntary worldwide recall of BIOCELL® textured breast implants and tissue expanders. Allergan is taking this action as a precaution following notification of recently updated global safety information concerning the...
Allergan Suspends Sales and Withdraws Supply of Textured Breast Implants in European Markets
- Action Being Taken Following CE Mark Expiration and Compulsory Recall Request by Agence Nationale de Securite du Médicament (ANSM) - DUBLIN, Dec. 19, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that the company has suspended sales ...
Allergan Announces Plans to Build First Medical Aesthetics Innovation Center in Chengdu China
-- Innovation Center to Feature State-of-the-Art Medical Aesthetics Training Center for Practitioners, Education and Experience Center for Consumers -- Allergan Expects to Train 3,000 Medical Aesthetics Practitioners Per Year Through New Center -- Announcement Follows Recent Memorandum of Unders...
Ozurdex(R) (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion
-- An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii -- DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc (NYSE:AGN) announces the launch of Ozurdex® (dexamethasone intravitreal implant 0.7 mg) in China for the treatment of adult patients...
Allergan's BELKYRA® (Deoxycholic Acid) Receives Marketing Authorisation In Sweden For The Treatment Of Moderate To Severe Fullness Under The Chin (Double Chin)
DUBLIN, Oct. 13, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) a leading global pharmaceutical company, announced thatSweden has received the Marketing Authorisation for BELKYRA® (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA). BELKYRA® is a prescripti...
New Global Research From Allergan Shows New Attitude To Beauty As Women Seek Confidence Over Youth
DUBLIN, June 28, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a global medical aesthetics company and the makers of Juvéderm® facial fillers today announces the results of a new global beauty trends study. It reveals women are more aware and open to aesthetic enhancement and are taking control ...
